Design and Discovery of New Dual Carbonic Anhydrase IX and VEGFR‐2 Inhibitors Based on the Benzenesulfonamide‐Bearing 4‐Thiazolidinones/2,4‐Thiazolidinediones Scaffold DOI Open Access
Merve Zengin, Oya Ünsal Tan, Suna Sabuncuoğlu

et al.

Drug Development Research, Journal Year: 2024, Volume and Issue: 85(8)

Published: Dec. 1, 2024

Dual-targeting drug design has become a popular approach in investigating and developing potent anticancer agents. In this regard, carbonic anhydrase (CAIX) vascular endothelial growth factor receptor (VEGFR-2) are emerging as highly effective targets the battle against cancer. present study, two series of 4-thiazolidinones/2,4-thiazolidinediones carrying 2-methylbenzenesulfonamide derivatives were designed synthesized potential dual CAIX/VEGFR-2 inhibitors. All target compounds evaluated CAIX enzyme compared to dorzolamide acetazolamide, subsequently most inhibitors (3a, 3b, 3o, 6d, 6g, 6i) selected evaluate their inhibitory activity VEGFR-2 using sorafenib reference drug. These also MCF-7 breast cancer cells murine fibroblast 3T3 cell line. According results, 3b (CAIX IC

Language: Английский

Thiazolidinedione derivatives: emerging role in cancer therapy DOI

Ganesh Latambale,

Kapil Juvale

Molecular Diversity, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

Language: Английский

Citations

0
Redefining the significance of quinoline containing compounds as potent VEGFR-2 inhibitors for cancer therapy DOI

Jurnal Reang,

Vinita Sharma, Vivek Yadav

et al.

Medicinal Chemistry Research, Journal Year: 2024, Volume and Issue: 33(7), P. 1079 - 1099

Published: June 27, 2024

Language: Английский

Citations

3
Integrated in silico and in vitro discovery of a new anticancer thiadiazole analog targeting VEGFR-2 DOI
Ibrahim H. Eissa, Hazem Elkady, Walid E. Elgammal

et al.

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1312, P. 138641 - 138641

Published: May 15, 2024

Language: Английский

Citations

2
Design, Synthesis, and Biological Evaluation of Novel Heterocyclic Derivatives of 2,4‐Thiazolidine Dione as Anti‐Cancer Agents DOI Creative Commons
Kiran Kumar Vunnam, Naresh Kumar Katari, Nagalakshmi Jeedimalla

et al.

Applied Research, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 13, 2024

ABSTRACT This study explores the development of novel 2,4‐thiazolidinedione derivatives as potential anticancer agents. We report synthesis 15 analogs utilizing a strategic approach focused on intermediate diversification. Key intermediates, (Z)‐5‐([1,1′‐biphenyl]‐4‐ylmethylene)thiazolidine‐2,4‐dione 5a and (Z)‐5‐(benzo[1,3]dioxol‐5‐ylmethylene)thiazolidine‐2,4‐dione 5b , were synthesized via Knoevenagel condensation acetal formation reactions, respectively. Subsequent N‐alkylation reactions provided platform for introducing diverse functionalities exploring structure–activity relationships to optimize medicinal chemistry profile these compounds. The compounds tested against various human cancer cell lines, including breast (MCF‐7, MDA‐MB‐453), lung (A549), prostate (PC‐3) cancers, using an MTT assay. Compounds 8c 10g emerged particularly promising, exhibiting activity all lines with IC 50 values between 3.41 ± 0.51 40 μM. These also induced apoptosis, suggesting that they inhibit proliferation through this death pathway. Moreover, relative molecular docking studies evidence compound likely functions by intercalating DNA.

Language: Английский

Citations

1
Synthesis, Characterization, Bioactivity Evaluation, and POM/DFT/Docking Analysis of Novel Thiazolidine Derivatives as Potent Anticancer and Antifungal Agents DOI

Ahmed A. Majed,

Qeaser R. Abdalzahra,

Hamsa Hussein Al-Hujaj

et al.

ChemistrySelect, Journal Year: 2024, Volume and Issue: 9(40)

Published: Oct. 1, 2024

Abstract A series of 2,2′‐(1,4‐phenylene)bis(N‐substituted phenylthiazolidine‐4‐amide) derivatives, denoted as (A 3–9 ), were synthesized, and characterized for their potential applications against prostate cancer cells (PC3), Candida albicans fungi. These compounds incorporate various substituents on the phenyl ring such 4‐NO 2 , 3‐NO 4‐COCH 3 4‐H, 4‐OCH CH 4‐Cl. The chemical structures these derivatives confirmed by NMR, FTIR, mass spectroscopy. Biological assays, utilizing MTT assay (PC3) disk diffusion fungi, conducted to evaluate bioactivity compounds. results revealed promising cytotoxic antifungal activities. Specifically, (IC 50 =69.74±0.96), 4 =63.64±0.950), 9 =57.14±0.88 μg/mL) exhibited notable potency PC3 cells, while 7 8 considerable efficacy with MIC 312 μg/mL. Moreover, density functional theory (DFT) simulations used study electronic properties reactivity descriptors energy gap ( E g ionization IP electron affinity EA (μ), hardness η global softness (σ), electronegativity (χ), electrophilicity (ω) gain a better understanding Structure‐Activity Relationship (SAR). Molecular docking analysis DNA Gyrase EGFR tyrosine kinase enzymes strong binding interactions investigated molecules within active sites, making them valuable candidates further development therapeutic agents fungal infections. POM indicates presence two pharmacophore sites (O1 δ− O2 ) (O3 O4 well antitumor NH1 δ+ (O4 NH2 ).

Language: Английский

Citations

0
Design and Discovery of New Dual Carbonic Anhydrase IX and VEGFR‐2 Inhibitors Based on the Benzenesulfonamide‐Bearing 4‐Thiazolidinones/2,4‐Thiazolidinediones Scaffold DOI Open Access
Merve Zengin, Oya Ünsal Tan, Suna Sabuncuoğlu

et al.

Drug Development Research, Journal Year: 2024, Volume and Issue: 85(8)

Published: Dec. 1, 2024

Dual-targeting drug design has become a popular approach in investigating and developing potent anticancer agents. In this regard, carbonic anhydrase (CAIX) vascular endothelial growth factor receptor (VEGFR-2) are emerging as highly effective targets the battle against cancer. present study, two series of 4-thiazolidinones/2,4-thiazolidinediones carrying 2-methylbenzenesulfonamide derivatives were designed synthesized potential dual CAIX/VEGFR-2 inhibitors. All target compounds evaluated CAIX enzyme compared to dorzolamide acetazolamide, subsequently most inhibitors (3a, 3b, 3o, 6d, 6g, 6i) selected evaluate their inhibitory activity VEGFR-2 using sorafenib reference drug. These also MCF-7 breast cancer cells murine fibroblast 3T3 cell line. According results, 3b (CAIX IC

Language: Английский

Citations

0